钠-葡萄糖共转运蛋白2抑制剂对糖尿病相关眼病的影响  

Effects of sodium-glucose cotransporter 2 inhibitors on ocular diseases in patients with diabetes mellitus

作　　者：王雪 张真稳 Wang Xue;Zhang Zhenwen(Northern Jiangsu People′s Hospital Affiliated to Yangzhou University,Yangzhou,225000,China)

机构地区：[1]扬州大学附属苏北人民医院,扬州225000

出　　处：《国际内分泌代谢杂志》2024年第3期198-201,共4页International Journal of Endocrinology and Metabolism

基　　金：江苏省中医药科技发展计划项目(YB2020087);国家自然科学基金项目(82374100)。

摘　　要：眼是糖尿病主要损害的靶器官之一,糖尿病相关眼病是一组严重影响患者视觉质量乃至致盲的疾病。目前的临床治疗大多适用于眼病晚期,亟需相关防治眼病发生发展的药物。钠-葡萄糖共转运蛋白2抑制剂(SGLT2i)是用于降低糖尿病患者高血糖的新型口服药物,在糖尿病相关性心血管和肾脏疾病已表现出高度有益作用。目前,利用SGLT2i降低血糖同时防治糖尿病相关眼部疾病也成为一个新的研究领域。本文主要综述了SGLT2i在糖尿病相关眼部疾病的研究进展。The eye is one of the major target organs damaged by diabetes,and diabetes-related eye diseases are a group of diseases that seriously affect the quality of vision of patients and even cause blindness.Most of the current clinical treatments are applicable to the advanced stages of eye disease,and there is an urgent need for drugs to prevent the development of eye disease.Sodium-Glucose Transporter 2 Inhibitors(SGLT2i)are novel oral drugs used to reduce hyperglycaemia in diabetic patients,and have shown highly beneficial effects in diabetes-associated cardiovascular and renal diseases.Currently,the use of SGLT2i to lower blood glucose while preventing diabetes-associated eye diseases has also become a new area of research.This article mainly reviews the research progress of SGLT2i in diabetes-related eye diseases.

关 键 词：钠-葡萄糖共转运蛋白2抑制剂 糖尿病性视网膜病变 糖尿病性白内障 糖尿病性角膜病变 

分 类 号：R587.2[医药卫生—内分泌] R771.3[医药卫生—内科学]